Business Wire

BDA

6.4.2021 21:47:05 CEST | Business Wire | Press release

Share
BDA to Spotlight Bermuda Market at RIMS Virtual Conference

The Bermuda Business Development Agency (BDA) will host a virtual panel discussion on Bermuda’s liability market and a Bermuda networking break as part of RIMS, the risk management society® annual conference, a comprehensive risk management event that connects and informs the risk management community. The BDA is proud to be a diamond sponsor of this year’s event, RIMS LIVE, which takes place from April 19–30.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210406006077/en/

The panel, titled “Changes and Trends in Liability Risk,” will be held on April 22 from 2–3 p.m. ADT. The session will feature Judy Gonsalves, division president at Chubb Bermuda; Saadia Savory, vice president and head of casualty Bermuda at Aspen Insurance; and Kirsten Beasley, interim head, Willis Towers Watson Bermuda. Moderated by Jasmine DeSilva, the BDA’s business development manager for risk and insurance solutions, the panel will explore the current state of the liability market, emerging trends, and the Bermuda market’s response.

“RIMS is the largest risk event of the year — it is a staple in the calendar and the Bermuda market has proudly attended for more than 35 years,” BDA’s CEO Roland Andy Burrows said. “The BDA and Bermuda are extensively committed to supporting and growing the risk management industry here, and participating in the RIMS annual conference is a key part of that. Bermuda continues to work hard to remain at the forefront of commercial trends and drives innovation forward as one of the world’s most important insurance and reinsurance hubs.”

For those who want to connect with Bermuda and the BDA, or find out more, the BDA will host a virtual booth where delegates can learn more about the market, view videos, and engage in live chat. Delegates can also schedule video meetings.

On a lighter note, the BDA will be bringing Bermuda to the attendees during the “Take a Break in Bermuda” networking event on April 20 at 4:30 p.m. ADT, providing an opportunity to hear from the Premier of Bermuda, the Hon. E. David Burt, JP, MP; Bermuda’s Minister of Finance, the Hon. Curtis Dickinson, JP, MP; and BDA CEO Roland Andy Burrows, who will all be speaking from the beautiful Hamilton Princess & Beach Club.

Also from the Hamilton Princess, Jasmine DeSilva and Andrew Holmes, Bermuda brand director for Goslings, will make Bermuda’s famous Rum Swizzle cocktail in Sheila Gosling’s Maytag vintage washing machine from 1964 — the same appliance Bermuda’s late social queen used to prepare drinks in the 1960s. The BDA will also announce the winner of an all-expenses paid trip to Bermuda, including a stay at the Hamilton Princess.

For more information on RIMS and to register for the conference, click here . To schedule a meeting with a BDA team member, please email jasmine@bda.bm or olivia@bda.bm . For more information on the BDA, click here .

CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye